Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 7:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Control Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects

NCT02141425
View directory record Official record
Conditions
Healthy Volunteers, Pharmacokinetics of ASP015K
Interventions
ASP015K, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

NCT01037543
View directory record Official record
Conditions
Healthy
Interventions
HM10460A or placebo or Neulasta
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
20 Years to 45 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

NCT01461993
View directory record Official record
Conditions
Vaccines, Meningococcal Vaccines
Interventions
rLP2086 and Gardasil, rLP2086, Gardasil
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 17 Years
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
87
States / cities
Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

NCT04766931
View directory record Official record
Conditions
Covid19
Interventions
FB2001, FB2001 Placebo
Drug
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Jun 7, 2026, 7:46 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males

NCT03222401
View directory record Official record
Conditions
Neisseria Gonorrhoeae
Interventions
1 mg/kg single infusion of F598, 3 mg/kg single infusion of F598, 10 mg/kg single infusion of F598
Drug
Lead sponsor
Alopexx Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short Term Hemodynamic Effects of Controlled Slow Breathing With Biofeedback in Patients With Heart Failure

NCT00971386
View directory record Official record
Conditions
Heart Failure
Interventions
Slow breathing
Behavioral
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

NCT04688632
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions
Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jun 7, 2026, 7:46 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

NCT07425392
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, PCV20
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
30
States / cities
Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 7, 2026, 7:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

NCT01150812
View directory record Official record
Conditions
Thrombin Inhibition
Interventions
AZD8165
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV

NCT04380207
View directory record Official record
Conditions
Bacterial Infections
Interventions
QPX7728, Placebo, QPX2014
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

TAK-935 Multiple Rising Dose Study in Healthy Participants

NCT02539134
View directory record Official record
Conditions
Epilepsy
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

NCT01941511
View directory record Official record
Conditions
Healthy
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Intravenous Nafithromycin

NCT03981887
View directory record Official record
Conditions
Healthy
Interventions
Nafithromycin, Placebo
Drug · Other
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

NCT03418493
View directory record Official record
Conditions
Psoriasis
Interventions
LY3316531 - IV, LY3316531 - SC, Placebo - IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jun 7, 2026, 7:46 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
AMG 732, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Kissimmee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 7, 2026, 7:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

NCT01164904
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Amg 181
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Glendale, California • Danbury, Connecticut • Plymouth, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male

NCT04138849
View directory record Official record
Conditions
Healthy Participants
Interventions
BBT-877 single dose, Placebo single dose
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers

NCT04876924
View directory record Official record
Conditions
Healthy
Interventions
BBP-711, Placebo
Drug
Lead sponsor
Cantero Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

NCT04142424
View directory record Official record
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

NCT04052360
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cenerimod, Matching Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

NCT00708903
View directory record Official record
Conditions
Breast Cancer
Interventions
neratinib, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2012 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.

NCT06697223
View directory record Official record
Conditions
Healthy Subjects
Interventions
INTERCEPT Blood System for Platelets with LED Illuminator
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Norfolk, Virginia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

NCT01364974
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of ASP015K, Pharmacodynamics
Interventions
ASP015K, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Jun 7, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing

NCT01892891
View directory record Official record
Conditions
Healthy
Interventions
VBY-036
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Jun 7, 2026, 7:46 AM EDT